查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1608077

In Silico药物发现市场：按分子类型、工作流程、治疗领域和最终用户 - 2025-2030 年全球预测

In-Silico Drug Discovery Market by Molecule Type (Antibodies, Nucleic Acids, Peptides), Workflow (Bioinformatics, Clinical Trials, Discovery), Therapeutic Area, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023 年，In Silico药物发现市值为 26.9 亿美元，预计到 2024 年将达到 28.6 亿美元，复合年增长率为 8.71%，到 2030 年将达到 48.3 亿美元。

In Silico药物发现利用计算方法来设计和优化药物，透过加快药物开发步伐并降低相关成本，正在重新定义製药业。它包括电脑辅助药物设计、分子建模和预测药物与其标靶之间相互作用的模拟。对In Silico方法的需求源自于提高研发生产力的迫切需求。这些技术将应用于先导化合物的识别、优化和毒性预测，以提高药物开发的准确性。最终用户主要是製药公司、生技公司、研究机构和学术机构。该市场是由处方分析的显着进步、处理器功能的增强以及对个人化药物的需求不断增长所推动的。此外，人工智慧和机器学习的日益采用将进一步提高药物发现过程的效率。一个关键的机会在于快速发展的基因组学领域，其中促进根据基因图谱定制的个人化药物发现In Silico工具正在吸引大量的研究和投资。然而，这个市场面临着初始成本高、资料隐私问题以及缺乏熟悉计算技术的熟练人员等挑战。准确复製复杂生物系统的技术限制也仍然是一个障碍。专注于结合电脑模拟、体外和体内资料的整合平台的创新可以提供竞争优势。云端基础的灵活建模和协作解决方案也具有改变产业的巨大潜力。公司应优先开发直觉的使用者介面和培训计划，以克服技能差距。总体而言，由于技术进步和综合疗法相关的机会，In Silico药物发现市场呈现出充满希望的前景，而克服经济和技术挑战将是成长的条件。

主要市场统计
基准年[2023] 26.9亿美元
预测年份 [2024] 28.6亿美元
预测年份 [2030] 48.3亿美元
复合年增长率（%） 8.71%

市场动态：揭示快速发展的电脑In Silico药物发现市场的关键市场洞察

供需的动态交互作用正在改变In Silico药物发现市场。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 疾病盛行率上升和药物发现
    • 改进计算模型和模拟
    • 个性化医疗的趋势
  • 市场限制因素
    • 资料整合问题
  • 市场机会
    • 先进技术在In Silico药物发现的整合
    • 持续研究和开发，推动In Silico药物发现创新
  • 市场挑战
    • 流程复杂且缺乏熟练的专业人员

波特五力：驾驭In Silico药物发现市场的策略工具

波特的五力框架是了解In Silico药物发现市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解电脑In Silico药物发现市场的外部影响

外部宏观环境因素在塑造In Silico药物发现市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解In Silico药物发现市场的竞争状况

In Silico药物发现市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的见解，以应对日益激烈的竞争。

In Silico药物发现市场 FPNV 定位矩阵中供应商的绩效评估

FPNV 定位矩阵是评估In Silico药物发现市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议绘製电脑模拟In Silico发现市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，In Silico药物发现市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点关注可望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 疾病传播和新药发现的增加
      • 改进计算模型和模拟
      • 个性化医疗方法的趋势
    • 抑制因素
      • 资料整合问题
    • 机会
      • 将先进技术融入In Silico药物发现中
      • 持续研究和开发，推动In Silico药物发现创新
    • 任务
      • 流程复杂且缺乏熟练的专业人员
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第 6 章按分子类型In Silico药物发现市场

  • 抗体
  • 核酸
  • 胜肽
  • 蛋白质
  • 向量

第 7 章In Silico药物发现市场：依工作流程

  • 生物资讯学
  • 临床试验
  • 发现
  • 临床前测试
  • 蛋白质结构预测
  • 反向对接
  • 目标识别

第 8 章按治疗领域In Silico药物发现市场

  • 血液疾病
  • 感染疾病
  • 精神障碍
  • 代谢紊乱
  • 肌肉骨骼疾病
  • 神经系统疾病
  • 肿瘤性疾病
  • 呼吸系统疾病
  • 皮肤病

第 9 章In Silico药物发现市场：按最终用户

  • 学术研究所
  • 合约调查机构
  • 药品製造商

第 10 章 美洲In Silico药物发现市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太地区In Silico药物发现市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章欧洲、中东和非洲的In Silico药物发现市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Abzena Ltd.
  • Aragen Life Sciences Pvt. Ltd.
  • BioDuro LLC
  • BioNTech SE
  • Certara, Inc.
  • Charles River Laboratories International, Inc.
  • Chemical Computing Group ULC
  • ChemPartner PharmaTech Co Ltd
  • Creative Biostructure
  • Curia Global Inc.
  • Evotec SE
  • GenScript Biotech Corporation
  • InSilico Medicine
  • Ligand Pharmaceuticals Incorporated
  • Schrodinger Inc.
  • Selvita SA
  • Simulations Plus, Inc.
  • Sygnature Discovery
  • Viva Biotech Holding Group
  • WuXi AppTec
Product Code: MRR-2E76C3E47FCA

The In-Silico Drug Discovery Market was valued at USD 2.69 billion in 2023, expected to reach USD 2.86 billion in 2024, and is projected to grow at a CAGR of 8.71%, to USD 4.83 billion by 2030.

In-silico drug discovery, which leverages computational methods to design and optimize drugs, is redefining the pharmaceutical landscape by accelerating the pace of drug development and reducing associated costs. It encompasses computer-aided drug design, molecular modeling, and simulations to predict interactions between drugs and their targets. The necessity of in-silico approaches stems from the pressing need to enhance R&D productivity, especially as traditional methods prove costly and time-consuming. These technologies find application in lead identification, optimization, and toxicity prediction, enhancing the precision of drug development. End-users primarily include pharmaceutical and biotechnology companies, research organizations, and academic institutions. The market is poised for growth, driven by significant prescriptive analytics advancements, enhanced processor capabilities, and escalating demand for personalized medicines. Additionally, the increasing adoption of AI and machine learning further boosts efficiency in drug discovery processes. A key opportunity lies in the burgeoning field of genomics, with in-silico tools facilitating personalized drug discovery tailored to genetic profiles, thereby attracting substantial research and investment. However, this market faces challenges such as high initial costs, data privacy concerns, and a shortage of skilled personnel proficient in computational methods. Technological limitations in accurately replicating the complexity of biological systems remain a hurdle. Innovations focusing on integrated platforms combining in-silico, in-vitro, and in-vivo data could provide competitive advantages. Cloud-based solutions for flexible modeling and collaboration also hold significant potential for transformative industry change. Companies should prioritize developing intuitive user interfaces and training programs to overcome the skills gap. Overall, while the in-silico drug discovery market presents a promising horizon with opportunities tied to technological advancement and integrated therapies, growth is contingent upon navigating economic and technical challenges.

KEY MARKET STATISTICS
Base Year [2023] USD 2.69 billion
Estimated Year [2024] USD 2.86 billion
Forecast Year [2030] USD 4.83 billion
CAGR (%) 8.71%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving In-Silico Drug Discovery Market

The In-Silico Drug Discovery Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of diseases and increase in drug discovery
    • Improvement in computational models and simulations
    • Inclination towards personalized medicine approach
  • Market Restraints
    • Concerns associated with data integration
  • Market Opportunities
    • Integration of advanced technologies in in-silico drug discovery
    • Ongoing R&D to drive innovation in in-silico drug discovery
  • Market Challenges
    • Complex process and dearth of skilled professionals

Porter's Five Forces: A Strategic Tool for Navigating the In-Silico Drug Discovery Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the In-Silico Drug Discovery Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the In-Silico Drug Discovery Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the In-Silico Drug Discovery Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the In-Silico Drug Discovery Market

A detailed market share analysis in the In-Silico Drug Discovery Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the In-Silico Drug Discovery Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the In-Silico Drug Discovery Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the In-Silico Drug Discovery Market

A strategic analysis of the In-Silico Drug Discovery Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the In-Silico Drug Discovery Market, highlighting leading vendors and their innovative profiles. These include Abzena Ltd., Aragen Life Sciences Pvt. Ltd., BioDuro LLC, BioNTech SE, Certara, Inc., Charles River Laboratories International, Inc., Chemical Computing Group ULC, ChemPartner PharmaTech Co Ltd, Creative Biostructure, Curia Global Inc., Evotec SE, GenScript Biotech Corporation, InSilico Medicine, Ligand Pharmaceuticals Incorporated, Schrodinger Inc., Selvita S.A., Simulations Plus, Inc., Sygnature Discovery, Viva Biotech Holding Group, and WuXi AppTec.

Market Segmentation & Coverage

This research report categorizes the In-Silico Drug Discovery Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Molecule Type, market is studied across Antibodies, Nucleic Acids, Peptides, Proteins, and Vectors.
  • Based on Workflow, market is studied across Bioinformatics, Clinical Trials, Discovery, Preclinical Tests, Protein Structure Prediction, Reverse Docking, and Target Identification.
  • Based on Therapeutic Area, market is studied across Blood Disorders, Infectious Diseases, Mental Disorders, Metabolic Disorders, Musculoskeletal Disorders, Neurological Disorders, Oncological Disorders, Respiratory Disorders, and Skin Disorders.
  • Based on End User, market is studied across Academic & Research Institutes, Contract Research Organizations, and Pharmaceutical Manufacturers.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of diseases and increase in drug discovery
      • 5.1.1.2. Improvement in computational models and simulations
      • 5.1.1.3. Inclination towards personalized medicine approach
    • 5.1.2. Restraints
      • 5.1.2.1. Concerns associated with data integration
    • 5.1.3. Opportunities
      • 5.1.3.1. Integration of advanced technologies in in-silico drug discovery
      • 5.1.3.2. Ongoing R&D to drive innovation in in-silico drug discovery
    • 5.1.4. Challenges
      • 5.1.4.1. Complex process and dearth of skilled professionals
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. In-Silico Drug Discovery Market, by Molecule Type

  • 6.1. Introduction
  • 6.2. Antibodies
  • 6.3. Nucleic Acids
  • 6.4. Peptides
  • 6.5. Proteins
  • 6.6. Vectors

7. In-Silico Drug Discovery Market, by Workflow

  • 7.1. Introduction
  • 7.2. Bioinformatics
  • 7.3. Clinical Trials
  • 7.4. Discovery
  • 7.5. Preclinical Tests
  • 7.6. Protein Structure Prediction
  • 7.7. Reverse Docking
  • 7.8. Target Identification

8. In-Silico Drug Discovery Market, by Therapeutic Area

  • 8.1. Introduction
  • 8.2. Blood Disorders
  • 8.3. Infectious Diseases
  • 8.4. Mental Disorders
  • 8.5. Metabolic Disorders
  • 8.6. Musculoskeletal Disorders
  • 8.7. Neurological Disorders
  • 8.8. Oncological Disorders
  • 8.9. Respiratory Disorders
  • 8.10. Skin Disorders

9. In-Silico Drug Discovery Market, by End User

  • 9.1. Introduction
  • 9.2. Academic & Research Institutes
  • 9.3. Contract Research Organizations
  • 9.4. Pharmaceutical Manufacturers

10. Americas In-Silico Drug Discovery Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific In-Silico Drug Discovery Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa In-Silico Drug Discovery Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abzena Ltd.
  • 2. Aragen Life Sciences Pvt. Ltd.
  • 3. BioDuro LLC
  • 4. BioNTech SE
  • 5. Certara, Inc.
  • 6. Charles River Laboratories International, Inc.
  • 7. Chemical Computing Group ULC
  • 8. ChemPartner PharmaTech Co Ltd
  • 9. Creative Biostructure
  • 10. Curia Global Inc.
  • 11. Evotec SE
  • 12. GenScript Biotech Corporation
  • 13. InSilico Medicine
  • 14. Ligand Pharmaceuticals Incorporated
  • 15. Schrodinger Inc.
  • 16. Selvita S.A.
  • 17. Simulations Plus, Inc.
  • 18. Sygnature Discovery
  • 19. Viva Biotech Holding Group
  • 20. WuXi AppTec

LIST OF FIGURES

  • FIGURE 1. IN-SILICO DRUG DISCOVERY MARKET RESEARCH PROCESS
  • FIGURE 2. IN-SILICO DRUG DISCOVERY MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULE TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY WORKFLOW, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY WORKFLOW, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES IN-SILICO DRUG DISCOVERY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES IN-SILICO DRUG DISCOVERY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC IN-SILICO DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC IN-SILICO DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. IN-SILICO DRUG DISCOVERY MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. IN-SILICO DRUG DISCOVERY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. IN-SILICO DRUG DISCOVERY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. IN-SILICO DRUG DISCOVERY MARKET DYNAMICS
  • TABLE 7. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY NUCLEIC ACIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY PEPTIDES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY PROTEINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY VECTORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY BIOINFORMATICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY CLINICAL TRIALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DISCOVERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY PRECLINICAL TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY PROTEIN STRUCTURE PREDICTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY REVERSE DOCKING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TARGET IDENTIFICATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY BLOOD DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MENTAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MUSCULOSKELETAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ONCOLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY RESPIRATORY DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY SKIN DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY PHARMACEUTICAL MANUFACTURERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 40. ARGENTINA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. ARGENTINA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 42. ARGENTINA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 43. ARGENTINA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 44. BRAZIL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. BRAZIL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 46. BRAZIL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 47. BRAZIL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 48. CANADA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. CANADA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 50. CANADA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 51. CANADA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 52. MEXICO IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. MEXICO IN-SILICO DRUG DISCOVERY MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 54. MEXICO IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 55. MEXICO IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES IN-SILICO DRUG DISCOVERY MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 58. UNITED STATES IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 59. UNITED STATES IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 60. UNITED STATES IN-SILICO DRUG DISCOVERY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC IN-SILICO DRUG DISCOVERY MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 65. ASIA-PACIFIC IN-SILICO DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 66. AUSTRALIA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. AUSTRALIA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 68. AUSTRALIA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 69. AUSTRALIA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 70. CHINA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. CHINA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 72. CHINA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 73. CHINA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 74. INDIA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. INDIA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 76. INDIA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 77. INDIA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 78. INDONESIA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. INDONESIA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 80. INDONESIA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 81. INDONESIA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 82. JAPAN IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. JAPAN IN-SILICO DRUG DISCOVERY MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 84. JAPAN IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 85. JAPAN IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 86. MALAYSIA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. MALAYSIA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 88. MALAYSIA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 89. MALAYSIA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 90. PHILIPPINES IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. PHILIPPINES IN-SILICO DRUG DISCOVERY MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 92. PHILIPPINES IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 93. PHILIPPINES IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 94. SINGAPORE IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. SINGAPORE IN-SILICO DRUG DISCOVERY MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 96. SINGAPORE IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 97. SINGAPORE IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 98. SOUTH KOREA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. SOUTH KOREA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 100. SOUTH KOREA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 101. SOUTH KOREA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 102. TAIWAN IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. TAIWAN IN-SILICO DRUG DISCOVERY MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 104. TAIWAN IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 105. TAIWAN IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 106. THAILAND IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. THAILAND IN-SILICO DRUG DISCOVERY MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 108. THAILAND IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 109. THAILAND IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 110. VIETNAM IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. VIETNAM IN-SILICO DRUG DISCOVERY MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 112. VIETNAM IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 113. VIETNAM IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 119. DENMARK IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. DENMARK IN-SILICO DRUG DISCOVERY MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 121. DENMARK IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 122. DENMARK IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 123. EGYPT IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. EGYPT IN-SILICO DRUG DISCOVERY MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 125. EGYPT IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 126. EGYPT IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 127. FINLAND IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. FINLAND IN-SILICO DRUG DISCOVERY MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 129. FINLAND IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 130. FINLAND IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 131. FRANCE IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. FRANCE IN-SILICO DRUG DISCOVERY MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 133. FRANCE IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 134. FRANCE IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 135. GERMANY IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. GERMANY IN-SILICO DRUG DISCOVERY MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 137. GERMANY IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 138. GERMANY IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 139. ISRAEL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. ISRAEL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 141. ISRAEL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 142. ISRAEL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 143. ITALY IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. ITALY IN-SILICO DRUG DISCOVERY MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 145. ITALY IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 146. ITALY IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 147. NETHERLANDS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. NETHERLANDS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 149. NETHERLANDS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 150. NETHERLANDS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 151. NIGERIA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. NIGERIA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 153. NIGERIA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 154. NIGERIA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 155. NORWAY IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. NORWAY IN-SILICO DRUG DISCOVERY MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 157. NORWAY IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 158. NORWAY IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 159. POLAND IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. POLAND IN-SILICO DRUG DISCOVERY MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 161. POLAND IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 162. POLAND IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 163. QATAR IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. QATAR IN-SILICO DRUG DISCOVERY MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 165. QATAR IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 166. QATAR IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 167. RUSSIA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. RUSSIA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 169. RUSSIA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 170. RUSSIA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 171. SAUDI ARABIA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. SAUDI ARABIA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 173. SAUDI ARABIA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 174. SAUDI ARABIA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 175. SOUTH AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. SOUTH AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 177. SOUTH AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 178. SOUTH AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 179. SPAIN IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. SPAIN IN-SILICO DRUG DISCOVERY MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 181. SPAIN IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 182. SPAIN IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 183. SWEDEN IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. SWEDEN IN-SILICO DRUG DISCOVERY MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 185. SWEDEN IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 186. SWEDEN IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 187. SWITZERLAND IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. SWITZERLAND IN-SILICO DRUG DISCOVERY MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 189. SWITZERLAND IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 190. SWITZERLAND IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 191. TURKEY IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 192. TURKEY IN-SILICO DRUG DISCOVERY MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 193. TURKEY IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 194. TURKEY IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 195. UNITED ARAB EMIRATES IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 196. UNITED ARAB EMIRATES IN-SILICO DRUG DISCOVERY MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 197. UNITED ARAB EMIRATES IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 198. UNITED ARAB EMIRATES IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 199. UNITED KINGDOM IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 200. UNITED KINGDOM IN-SILICO DRUG DISCOVERY MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 201. UNITED KINGDOM IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 202. UNITED KINGDOM IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 203. IN-SILICO DRUG DISCOVERY MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 204. IN-SILICO DRUG DISCOVERY MARKET, FPNV POSITIONING MATRIX, 2023